<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981069</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20160597H</org_study_id>
    <nct_id>NCT02981069</nct_id>
  </id_info>
  <brief_title>Effect of GLP-1 Receptor Agonist, Exenatide on Glucosuria Induced Elevation in ENDOGENOUS GLUCOSE PRODUCTION (EGP)</brief_title>
  <official_title>Effect of GLP-1 Receptor Agonist, Exenatide on Glucosuria Induced Elevation in ENDOGENOUS GLUCOSE PRODUCTION (EGP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous
      glucose production) and plasma glucose concentration in diabetic subjects. Researchers will
      examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and
      fall in plasma glucose concentration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine whether the coadministration of exenatide plus dapagliflozin will
      prevent the increase in EGP and result in an additive or even synergistic decrease in plasma
      glucose concentration compared to each agent alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Endogenous Glucose Production (EGP) for Dapagliflozin only</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following dapagliflozin alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EGP for Dapagliflozin plus exenatide (Byetta)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following dapagliflozin/exenatide (Byetta)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EGP for Dapagliflozin plus exenatide (Bydureon)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following dapagliflozin/exenatide (bydureon)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EGP for Exenatide (Byetta) vs dapagliflozin/exenatide</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following exenatide (byetta) alone versus dapagliflozin/exenatide (byetta)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EGP for dapagliflozin vs placebo</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following dapagliflozin alone versus the change in EGP following placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EGP for exenatide (byetta) vs placebo</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following dapagliflozin alone, exenatide alone, and dapagliflozin/exenatide versus the change in EGP following placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EGP for dapagliflozin/exenatide vs placebo</measure>
    <time_frame>16 weeks</time_frame>
    <description>The change in EGP above baseline following dapagliflozin/exenatide versus the change in EGP following placebo.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Byetta / Bydureon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exenatide:
4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Byetta/Bydureon plus Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exenatide:
4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc PLUS
Dapagliflozin:
4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group (4 weeks and 12 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>10mg</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_label>Byetta/Bydureon plus Dapagliflozin</arm_group_label>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)</description>
    <arm_group_label>Byetta / Bydureon</arm_group_label>
    <arm_group_label>Byetta/Bydureon plus Dapagliflozin</arm_group_label>
    <other_name>Byetta, Bydureon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for Dapagliflozin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI = 25-35 kg/m^2

          -  must be drug naïve and/or on a stable dose (more than 3 months) of metformin and/or
             sulfonylurea

          -  HbA1c &gt;7.0% and &lt;10.0%

          -  Other than diabetes, subjects must be in good general health as determined by physical
             exam, medical history, blood chemistries, CBC, TSH, T4, EKG and urinanalysis.

          -  Only subjects whose body weight has been stable (± 3 lbs) over the preceding three
             months and who do not participate in an excessively heavy exercise program will be
             included.

        Exclusion Criteria:

          -  Subjects taking drugs known to affect glucose metabolism (other than metformin and
             sulfonylurea) will be excluded

          -  Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine
             &gt;1.4 females or &gt;1.5 males, or 24-hour urine albumin excretion &gt; 300 mg will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugenio Cersosimo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugenio Cersosimo, MD, PhD</last_name>
    <phone>210-358-7200</phone>
    <email>cersosimo@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ralph DeFronzo, MD</last_name>
    <phone>210-567-6691</phone>
    <email>defronzo@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenio Cersosimo, MD</last_name>
      <phone>210-358-7200</phone>
      <email>cersosimo@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ralph A DeFronzo, MD</last_name>
      <phone>210-567-6691</phone>
      <email>defronzo@uthscsa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eugenio Cersosimo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Eugenio Cersosimo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

